1 / 4

PPAR and NOX Agonist_ Savior of Underserved Primary Biliary Cholangitis Patients

Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is an autoimmune condition that causes the periportal inflammatory cholestasis that results from the slow death of intrahepatic bile ducts. Cirrhosis and portal hypertension are the results of persistent hepatic cholestasis.

xmichael
Download Presentation

PPAR and NOX Agonist_ Savior of Underserved Primary Biliary Cholangitis Patients

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Revolutionizing Primary Biliary Cholangitis Treatment: The Emerging Role of PPAR and NOX Agonists PPAR and NOX Agonist: Savior of Underserved Primary Biliary Cholangitis Patients Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is an autoimmune condition that causes the periportal inflammatory cholestasis that results from the slow death of intrahepatic bile ducts. Cirrhosis and portal hypertension are the results of persistent hepatic cholestasis. UDCA and OCALIVA – The Only Available Therapies for Primary Biliary Cholangitis Treatment Despite Controversies

  2. Ursodeoxycholic acid (UDCA) and obeticholic acid are the only two primary biliary cholangitis drugs that the Food and Drug Administration (FDA) has approved for treating primary biliary cholangitis (OCALIVA). UDCA is still the go-to first-line treatment for primary biliary cholangitis despite the introduction of promising second-line therapies for PBC patients who are UDCA-intolerant or UDCA-naive. The UDCA's good long-term efficacy and safety profile and affordable primary biliary cholangitis treatment are the main reasons for the sustained trust. By enhancing hepatobiliary secretory function and lowering bile toxicity, UDCA has anti-cholestatic effects. Obeticholic acid (OCA), OCALIVA was the second medication to be approved for use in patients who had an inadequate response to UDCA or were intolerant as well as those who were UDCA-naive. For 40 to 80% of people with primary biliary cholangitis, fatigue is the most often reported symptom of their condition. Fatigue has crippling physical repercussions that affect patients' capacity to accomplish everyday tasks, and it also negatively affects their mental health, social life, family life, sexual life, and work performance. Musings on the Primary Biliary Cholangitis Treatment Seladelpar, being developed by CymaBay Therapeutics, elafibranor, setanaxib, saroglitazar Mg, and linerixibat are some of the promising PBC medications to hit the primary biliary cholangitis therapy market (GlaxoSmithKline). For the management and first treatment of biliary cholangitis in the 7MM+ China, all assets are now in the late stages of development. Primary Biliary Cholangitis Treatment Market All Set to Grow Significantly The market environment will benefit from the development of disease-specific medicines for the treatment of primary biliary cholangitis, which will then enable major changes during the forecast period (2019–2032). With improved diagnosis and safe and effective primary biliary cholangitis treatment options, the market for treating this condition is anticipated to increase significantly. However, difficulties with price and reimbursement, as well as related long-term side effects of approved medications, are two key factors that affect the market success of the future therapies for the primary biliary cholangitis treatment. Related Reports B Cell Chronic Lymphocytic Leukemia Market https://www.delveinsight.com/report-store/b-cell-chronic-lymphocytic-leukemia-market?u tm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's "B Cell Chronic Lymphocytic Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Chronic Lymphocytic Leukemia, historical and forecasted epidemiology as well as the B Cell Chronic Lymphocytic Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

  3. B-Cell Lymphomas Market https://www.delveinsight.com/report-store/b-cell-lymphomas-market?utm_source=abnew swire&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's "B-Cell Lymphomas Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Lymphomas, historical and forecasted epidemiology as well as the B-Cell Lymphomas market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Behcet’s Syndrome Market https://www.delveinsight.com/report-store/behcets-disease-market?utm_source=abnews wire&utm_medium=pressrelease&utm_campaign=gpr DelveInsight’s “Behcet’s Syndrome Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Behcet’s syndrome in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom. Neoantigen-based Personalized Cancer therapeutic Vaccines https://www.delveinsight.com/report-store/neoantigen-based-personalized-cancer-therap eutic-vaccines-competitive-landscape?utm_source=abnewswire&utm_medium=pressrele ase&utm_campaign=gpr DelveInsight’s “Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035” report delivers an in-depth understanding of the Neoantigen based Personalized Cancer therapeutic Vaccines and the Neoantigen-based personalized cancer therapeutic vaccines emerging market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Glioblastoma Multiforme Market https://www.delveinsight.com/report-store/glioblastoma-market?utm_source=abnewswir e&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's "Glioblastoma Multiforme Market Insights, Epidemiology and Market Forecast– 2032" report delivers an in-depth understanding of the Glioblastoma, historical and forecasted epidemiology as well as the Glioblastoma market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. Latest Reports By DelveInsight Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic

  4. Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market To know more about our Consulting Services, Click here: DelveInsight Healthcare Consulting https://www.delveinsight.com/consulting/competitive-intelligence-services?utm_source= blog&utm_medium=promotion&utm_campaign=gpr Recent Blog’s By DelveInsight: ● Insights Into The Cutaneous T-cell Lymphoma Treatment Market ● Roche’s HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape ● Emerging Role of Digital Health in the Field of Oncology ● How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape ● How are Technological Trends and Innovations Reshaping the Dementia Care ● Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market ● Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients ● Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market ● Evaluating the Key Trends and Technologies Shaping the Future of Dentistry

More Related